ALS Limited has finalized the acquisition of York Analytical Laboratories, Inc., a maneuver designed to fundamentally accelerate the group’s expansion into the high-growth Northeast United States environmental testing market. The strategic rationale for this transaction centers on a "regional-scale" play, merging the target's technical leadership in emerging contaminants with the group’s extensive global infrastructure and institutional capital. This fusion effectively creates a specialized powerhouse in the US Northeast, providing the organization with the scientific talent and analytical equipment required to address the increasing complexity of PFAS contamination issues and major infrastructure programs.

This transaction is part of the Business Services industry, which currently tracks an average EBITDA multiple of 11.3x since the beginning of 2026, a stable level compared to 2025. This data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.